Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
AJ Scheen - Nature reviews endocrinology, 2020 - nature.com
The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …
Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes
M Packer, CS Wilcox, JM Testani - Circulation, 2023 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial
Background Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2)
inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure …
inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure …
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
EM Boorsma, JC Beusekamp… - European journal of …, 2021 - Wiley Online Library
Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors improve clinical outcome in
patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet …
patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet …
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
A Marton, T Kaneko, JP Kovalik, A Yasui… - Nature Reviews …, 2021 - nature.com
Therapeutic inhibition of the sodium–glucose co-transporter 2 (SGLT2) leads to substantial
loss of energy (in the form of glucose) and additional solutes (in the form of Na+ and its …
loss of energy (in the form of glucose) and additional solutes (in the form of Na+ and its …
Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF
L Shen, SL Kristensen, O Bengtsson, M Böhm… - Heart Failure, 2021 - jacc.org
Objectives The purpose of this study was to assess the efficacy and safety of dapagliflozin in
patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in …
patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in …
Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of …
RA Scholtes, MHA Muskiet, MJB van Baar… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for heart
failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and …
failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and …
Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Background Sodium-glucose co-transporter 2 inhibitors might enhance erythropoiesis and
increase red blood cell mass. We assessed the long-term effects of canagliflozin on …
increase red blood cell mass. We assessed the long-term effects of canagliflozin on …
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease
H Liu, VS Sridhar, J Boulet, A Dharia, A Khan… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease
(CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …
(CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …